Health ❯ Medical Research ❯ Clinical Trials

Drug Development

PAR1 Targeting FDA-Approved Treatments Neurosurgery Teclistamab Oncology Immunology Parkinson's Disease Gene-Editing Treatments Innovative Treatments

BMS, BioNTech Small-Cell Lung Cancer Drug Posts 76% Tumor Reduction, Advances to Phase III

The readout highlights BMS’s partnership-led oncology strategy supported by cash-generating brands Eliquis and Opdivo.

PAR1 Receptor Drives Lung Lymphatic Remodeling to Accelerate Fluid Clearance